13-valent Pneumococcal Conjugate Vaccine and Haemophilus Influenzae-Tetanus Toxoid Conjugate Vaccine in Patient with Systemic Juvenile Idiopathic Arthritis Receiving Tocilizumab: Clinical Case
Ekaterina I. Alekseeva,
Dar’ya D. Van’kova,
Tatyana M. Dvoryakovskaya,
Kseniya B. Isaeva,
Rina V. Denisova,
Anna V. Mamutova,
Aleksandra M. Chomahidze,
Nikolay A. Mayanskiy,
Natalya E. Tkachenko,
Maria V. Kurdup,
Tatyana V. Radygina,
Irina V. Zubkova https://doi.org/10.15690/vsp.v18i3.2035
Abstract
Background. Vaccination coverage in patients with rheumatic diseases remains extremely low. Moreover, infections are the leading cause of death in such patients. Respiratory infections mortality is 2–5 times higher in adults with rheumatoid arthritis than in overall population. The most frequent infectious complications in patients receiving Tocilizumab (first-line drug for treatment of patients with systemic juvenile idiopathic arthritis (SJIA)) are pneumonia and acute sinusitis. Their clinical course differs: slight clinical presentation, reference ranges of laboratory tests of disease activity (ESR, C-reactive protein), significant changes in lungs and paranasal sinuses according to the computer tomography. Infectious complications development can cause aggravation of prior disease itself or due to temporary immunosuppressive therapy cessation. Clinical Case Description. The experience of immunization with 13-valent pneumococcal conjugate vaccine (PCV13) and haemophilus influenzae-tetanus toxoid conjugate vaccine in the 1,5 years old boy with SJIA receiving interleukin-6 receptor monoclonal antibody Tocilizumab is presented. The result of such vaccination was increase of pneumococcal and haemophilus influenzae antibodies levels by more than two times. Meanwhile vaccination had no negative impact on the prior disease course: the levels of predictors of prior disease aggravation such as protein S100 and highly sensitive C-reactive protein did not increase significantly in comparison with the period before vaccination. Conclusion. The efficiency and safety of immunization with PCV13 and haemophilus influenzae-tetanus toxoid conjugate vaccine in the child with SJIA receiving Tocilizumab is presented.
Keywords
children,
pneumococcal disease,
vaccination,
13-valent pneumococcal conjugate vaccine,
haemophilus influenzae-tetanus toxoid conjugate vaccine,
Tocilizumab,
systemic juvenile idiopathic arthritis
Supporting agencies: Not specified.
About the Authors
Ekaterina I. Alekseeva
National Medical Research Center of Children’s Health;
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Disclosure of interest: receiving research grants from Roche, Pfizer, Centocor, Novartis companies
Russian Federation
Disclosure of interest: receiving research grants from Roche, Pfizer, Centocor, Novartis companies
Dar’ya D. Van’kova
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest: contributor confirmed the absence of a reportable conflict of interests
Russian Federation
Disclosure of interest: contributor confirmed the absence of a reportable conflict of interests
Tatyana M. Dvoryakovskaya
National Medical Research Center of Children’s Health;
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Disclosure of interest: receiving research grants from Roche, Pfizer companies
Russian Federation
Disclosure of interest: receiving research grants from Roche, Pfizer companies
Kseniya B. Isaeva
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest: contributor confirmed the absence of a reportable conflict of interests
Russian Federation
Disclosure of interest: contributor confirmed the absence of a reportable conflict of interests
Rina V. Denisova
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest: receiving research grants from Roche, Centocor, Novartis companies
Russian Federation
Disclosure of interest: receiving research grants from Roche, Centocor, Novartis companies
Anna V. Mamutova
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest: contributor confirmed the absence of a reportable conflict of interests
Russian Federation
Disclosure of interest: contributor confirmed the absence of a reportable conflict of interests
Aleksandra M. Chomahidze
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest: contributor confirmed the absence of a reportable conflict of interests
Russian Federation
Disclosure of interest: contributor confirmed the absence of a reportable conflict of interests
Nikolay A. Mayanskiy
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest: contributor confirmed the absence of a reportable conflict of interests
Russian Federation
Disclosure of interest: contributor confirmed the absence of a reportable conflict of interests
Natalya E. Tkachenko
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest: contributor confirmed the absence of a reportable conflict of interests
Russian Federation
Disclosure of interest: contributor confirmed the absence of a reportable conflict of interests
Maria V. Kurdup
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest: contributor confirmed the absence of a reportable conflict of interests
Russian Federation
Disclosure of interest: contributor confirmed the absence of a reportable conflict of interests
Tatyana V. Radygina
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest: contributor confirmed the absence of a reportable conflict of interests
Russian Federation
Disclosure of interest: contributor confirmed the absence of a reportable conflict of interests
Irina V. Zubkova
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest: contributor confirmed the absence of a reportable conflict of interests
Russian Federation
Disclosure of interest: contributor confirmed the absence of a reportable conflict of interests
References
1. Alexeeva EI, Litvitskii PF. Yuvenilnyi revmatoidnyi artrit: etiologiya, patogenez, klinika, algoritmy diagnostiki i lecheniya. Rukovodstvo dlya vrachei, prepodavatelei, nauchnykh sotrudnikov. Ed by Baranov A.A. Moscow: VEDI; 2007. 368 p. (In Russ).
2. Alexeeva EI. Juvenile idiopathic arthritis: clinical picture, diagnosis, treatment. Current pediatrics. 2015;14(1):78–94. (In Russ). doi: 10.15690/ vsp.v14i1.1266.
3. Hurd A, Beukelman T. Infectious complications in juvenile idiopathic arthritis. Curr Rheumatol Rep. 2013;15(5):327. doi: 10.1007/ s11926-013-0327-1.
4. Rubbert-Roth A, Furst DE, Nebesky JM, et al. A review of recent advances using tocilizumab in the treatment of rheumatic diseases. Rheumatol Ther. 2018;5(1):21–42. doi: 10.1007/s40744-018-0102-x.
5. Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum. 2013;65(10):2499–2512. doi: 10.1002/art.38092.
6. Pinheiro FA, Souza DC, Sato EI. A study of multiple causes of death in rheumatoid arthritis. J Rheumatol. 2015;42(12): 2221–2228. doi: 10.3899/jrheum.150166.
7. Immunization, vaccinesand biologicals. Pneumococcal disease [Internet]. WHO; 2014. (In Russ). Доступно по: http://www.who.int/immunization/ diseases/pneumococcal/ru/. Ссылка активна на 21.03.2019.
8. Berntson L, Fasth A, Andersson-Gare B, et al. Construct validity of ILAR and EULAR criteria in juvenile idiopathic arthritis: a population based incidence study from the Nordic countries. International League of Associations for Rheumatology. European League Against Rheumatism. J Rheumatol. 2001;28(12):2737–2743.
9. Woo P, Southwood TR, Prieur AM, et al. Randomized, placebocontrolled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 2000;43(8):1849–1857. doi: 10.1002/1529-0131(200008) 4383.0.co;2-f.
10. Alexeeva EI, Dvoryakovskaya TM, Denisova RV, et al. Immunization with a pneumococcal polysaccharide vaccine in children with juvenile idiopathic arthritis without systemic manifestations: a prospective study. Current pediatrics. 2017;16(6):493–501. (In Russ). doi: 10.15690/vsp.v16i6.1822.
11. Petty RE, Southwood TR, Manners P, et al.; International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–392.
12. Klinicheskie rekomendatsii "Yunosheskij artrit s sistemnym nachalom" [Internet]. Moscow: Soyuz pediatrov Rossii; 2016. (In Russ). Доступно по: http://cr.rosminzdrav.ru/#!/recomend/58. Ссылка активна на 12.04.2019.
13. Gattorno M. Autoinflammatory diseases in children (The Lecture from 18th of September 2013, Conference «Topical Problems of Diagnostics and Treatment of Juvenile Rheumatoid Arthritis»; 18–20 of September, 2013, St. Petersburg). Current Pediatrics. 2014;13(2):55–64. (In Russ). doi: 10.15690/ vsp.v13i2.973.
14. Bracaglia C, Prencipe G, De Benedetti F. Macrophage Activation Syndrome: different mechanisms leading to a one clinical syndrome. Pediatr Rheumatol Online J. 2017;15(1):5. doi: 10.1186/s12969-016-0130-4.
15. Machado SH, Xavier RM. Safety of tocilizumab in the treatment of juvenile idiopathic arthritis. Expert Opin Drug Saf. 2017;16(4): 493–500. doi: 10.1080/14740338.2017.1303479.
16. Roszkiewicz J, Orczyk K, Smolewska E. Tocilizumab in the treatment of systemic-onset juvenile idiopathic arthritis — singlecentre experience. Reumatologia. 2018;56(5):279–284. doi: 10.5114/reum.2018.79497.
17. Grevich S, Shenoi S. Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition. Adolesc Health Med Ther. 2017;8:125–135. doi: 10.2147/ AHMT.S109495.
18. Highlights of prescribing information. These highlights do not include all the information needed to use Actemra safely and effectively. See full prescribing information for Actemra [cited 2019 June]. Available from: https://www.gene.com/download/pdf/ actemra_prescribing.pdf.
19. Keyser FD. Choice of biologic therapy for patients with rheumatoid arthritis: the infection perspective. Curr Rheumatol Rev. 2011;7(1):77–87 doi: 10.2174/157339711794474620.
20. Henrickson SE, Ruffner MA, Kwan M. Unintended immunological consequences of biologic therapy. Curr Allergy Asthma Rep. 2016;16(6):46. doi: 10.1007/s11882-016-0624-7.
21. Burke RA, White ND. Biologic disease-modifying antirheumatic drugs. PSAP; 2014. Chronic Illnesses II. Available from: https:// www.accp.com/docs/bookstore/psap/p14b2_m1ch.pdf.
22. Horneff G. Biologic-associated infections in pediatric rheumatology. Curr Rheumatol Rep. 2015;17(11):66. doi: 10.1007/ s11926-015-0542-z.
23. Moots RJ, Sebba A, Rigby W, et al. Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials. Rheumatology (Oxford). 2017;56(4):541–549. doi: 10.1093/rheumatology/ kew370.
24. Kostik MM, Dubko MF, Masalova VV, et al. Identification of the best cutoff points and clinical signs specific for early recognition of macrophage activation syndrome in active systemic juvenile idiopathic arthritis. Semin Arthritis Rheum. 2015;44(4):417–422. doi: 10.1016/j.semarthrit.2014.09.004.
25. Mori S, Ueki Y, Akeda Y, et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. Ann Rheum Dis. 2013;72(8):1362–1366. doi: 10.1136/ annrheumdis-2012-202658.
Review
For citations:
Alekseeva E.I., Van’kova D.D., Dvoryakovskaya T.M., Isaeva K.B., Denisova R.V., Mamutova A.V., Chomahidze A.M., Mayanskiy N.A., Tkachenko N.E., Kurdup M.V., Radygina T.V., Zubkova I.V. 13-valent Pneumococcal Conjugate Vaccine and Haemophilus Influenzae-Tetanus Toxoid Conjugate Vaccine in Patient with Systemic Juvenile Idiopathic Arthritis Receiving Tocilizumab: Clinical Case. Current Pediatrics. 2019;18(3):180-186. (In Russ.) https://doi.org/10.15690/vsp.v18i3.2035
Views:
907
Email this article 
